dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc
Published 5 years ago • 136 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:43
dr. brahmer explains pd-1 and pd-l1
-
1:21
dr. julie brahmer on the pd-1 targeted immunotherapy bms-93655 clinical trial
-
1:53
dr. brahmer on the role of pd-1 and pd-l1
-
0:31
copy of dr. brahmer on the role of immunotherapy in metastatic nsclc
-
0:58
dr. julie r. brahmer on immunotherapy development in lung cancer
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
0:19
copy of dr. brahmer on immunotherapy in stage iv nsclc
-
1:31
dr. brahmer on the role of immunotherapy in metastatic nsclc
-
1:03
dr. costa on biomarkers beyond pd-l1 for immunotherapy in nsclc
-
2:05
cancer immunotherapy in lung cancer discussed by dr. julie brahmer
-
1:56
dr. brahmer discusses the future of antibodies for lung cancer
-
5:02
going beyond pd-l1 testing for lung cancer immunotherapy
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
1:14
dr. brahmer on immunotherapy in stage iv nsclc
-
48:15
immunotherapy for lung cancer: pd-1 and beyond, with naiyer rizvi
-
1:23
dr. brahmer on biomarkers for immune response in nsclc
-
3:50
pd-l1 expression in nsclc
-
23:37
gracecast-103_lung-cancer_immunotherapy: yervoy, anti-pd-1, reolysin, talactoferrin by dr. brahmer
-
7:09
personalizing immunotherapy beyond pdl1 expression